Mani Foroohar
Stock Analyst at Leerink Partners
(2.22)
# 2,686
Out of 4,886 analysts
164
Total ratings
48.31%
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Downgrades: Market Perform | $37 → $8 | $2.96 | +170.27% | 11 | May 28, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $19 → $18 | $4.44 | +305.86% | 3 | Mar 24, 2025 | |
| RXRX Recursion Pharmaceuticals | Maintains: Market Perform | $7 → $6 | $5.36 | +11.94% | 8 | Feb 28, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $31 → $27 | $4.22 | +539.81% | 9 | Jan 13, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $45 → $72 | $20.28 | +255.03% | 2 | Nov 12, 2024 | |
| CAMP Camp4 Therapeutics | Initiates: Outperform | $17 | $1.46 | +1,064.38% | 1 | Nov 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $47 → $49 | $50.25 | -2.48% | 11 | Oct 17, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $47 → $46 | $43.19 | +6.51% | 15 | Oct 17, 2024 | |
| WVE Wave Life Sciences | Maintains: Outperform | $20 → $22 | $6.95 | +216.77% | 6 | Oct 16, 2024 | |
| IONS Ionis Pharmaceuticals | Upgrades: Outperform | $53 → $62 | $41.34 | +49.98% | 15 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $12.65 | +2.77% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $21.42 | +35.39% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $165 → $230 | $19.03 | +1,108.62% | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $4 | $5.42 | -26.20% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.74 | - | 10 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $3.80 | +715.79% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $0.63 | +1,006.19% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $17.54 | +128.05% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $111 → $93 | $32.54 | +185.80% | 17 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $86 → $84 | $11.12 | +655.40% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $2.86 | +144.76% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $20.30 | +279.31% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $144 → $143 | $317.50 | -54.96% | 11 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $5.84 | +2.74% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $54.82 | +38.64% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $1.60 | +2,025.00% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $20 | $2.40 | +733.33% | 6 | Jul 23, 2021 |
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Market Perform
Price Target: $37 → $8
Current: $2.96
Upside: +170.27%
Lexeo Therapeutics
Mar 24, 2025
Maintains: Outperform
Price Target: $19 → $18
Current: $4.44
Upside: +305.86%
Recursion Pharmaceuticals
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $5.36
Upside: +11.94%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $4.22
Upside: +539.81%
Neurogene
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $20.28
Upside: +255.03%
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: $17
Current: $1.46
Upside: +1,064.38%
Mirum Pharmaceuticals
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $49
Current: $50.25
Upside: -2.48%
BridgeBio Pharma
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $46
Current: $43.19
Upside: +6.51%
Wave Life Sciences
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $6.95
Upside: +216.77%
Ionis Pharmaceuticals
Jul 24, 2024
Upgrades: Outperform
Price Target: $53 → $62
Current: $41.34
Upside: +49.98%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $12.65
Upside: +2.77%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $21.42
Upside: +35.39%
Jun 24, 2024
Maintains: Outperform
Price Target: $165 → $230
Current: $19.03
Upside: +1,108.62%
Apr 25, 2024
Downgrades: Market Perform
Price Target: $12 → $4
Current: $5.42
Upside: -26.20%
Mar 6, 2024
Upgrades: Outperform
Price Target: n/a
Current: $8.74
Upside: -
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $3.80
Upside: +715.79%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $0.63
Upside: +1,006.19%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $17.54
Upside: +128.05%
Feb 24, 2023
Downgrades: Underperform
Price Target: $111 → $93
Current: $32.54
Upside: +185.80%
Jan 23, 2023
Maintains: Outperform
Price Target: $86 → $84
Current: $11.12
Upside: +655.40%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $2.86
Upside: +144.76%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $20.30
Upside: +279.31%
Jan 23, 2023
Maintains: Market Perform
Price Target: $144 → $143
Current: $317.50
Upside: -54.96%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $5.84
Upside: +2.74%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $54.82
Upside: +38.64%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $1.60
Upside: +2,025.00%
Jul 23, 2021
Maintains: Market Perform
Price Target: $50 → $20
Current: $2.40
Upside: +733.33%